Strategic partnerships MABT is actively pursuing collaboration opportunities in immunotherapy for infectious diseases and has demonstrated interest in partnering and licensing with external developers, including recent integration of XPose Therapeutics to expand their drug discovery capabilities.

Acquisition signals The February 2026 acquisition of XPose Therapeutics and integration of their drug discovery engine indicate a strategy to rapidly broaden the pipeline, creating joint value opportunities for BD teams in co-development, milestone-based licensing, and shared commercialization efforts.

Geographic expansion expansion of facilities to Songdo, Incheon, South Korea signaling readiness for regional R&D, manufacturing scale-up, and access to Asia-Pacific partnerships, suppliers, and clinical networks.

Regulatory incentives Orphan Drug Designation for rabies and a focus on fast-tracked FDA pathways present talking points for potential collaborators seeking accelerated approval timelines and extended exclusivity in niche infectious disease indications.

Financial and market signals With revenue in the low single-digit millions and external funding of five million, there is potential for investor-backed collaborations, milestone-rich deals, and co-funded programs leveraging MABT’s clinic-ready immunotherapy platform and AI-enabled development capabilities.